{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:10:31Z","timestamp":1776867031504,"version":"3.51.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Cutaneous adverse events are commonly reported immune-related adverse events (irAEs), some of which are serious or even life-threatening, and it is essential to study these specific cutaneous AEs to understand their characteristics and risk.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed a meta-analysis of published clinical trials for immune checkpoint inhibitors (ICIs) to evaluate the incidence of cutaneous adverse events, using data from PubMed, Embase, and the Cochrane Library databases.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 232 trials with 45,472 patients were involved. Results showed that anti-PD-1 and targeted therapy combinations were associated with higher risk for most of the selected cutaneous adverse events. In addition, a retrospective pharmacovigilance study was conducted using the Food and Drug Administration (FDA) Adverse Events System database. Reporting odds ratio (ROR) and Bayesian information components (IC) were used to perform the disproportionality analysis. Cases were extracted from January 2011 to September 2020. We identified 381 (20.24%) maculopapular rash, 213 (11.32%) vitiligo, 215 (11.42%) Stevens\u2010Johnson syndrome (SJS), and 165 (8.77%) toxic epidermal necrolysis (TEN) cases. For vitiligo, anti-PD-1\/L1 combined with anti-CTLA-4 therapy showed the strongest signal (ROR: 55.89; 95% CI: 42.34\u201373.78; IC<jats:sub>025<\/jats:sub>: 4.73). Palmar-plantar erythrodysesthesia (PPE) was reported with the most significant association with combined anti-PD-1\/L1 and VEGF (R)-TKIs (ROR: 18.67; 95% CI: 14.77\u201323.60; IC<jats:sub>025<\/jats:sub>: 3.67). For SJS\/TEN, antiPD-1 inhibitors showed the strongest signal (ROR: 3.07; 95% CI: 2.68\u20133.52; IC<jats:sub>025<\/jats:sub>: 1.39). The median onset time of vitiligo and SJS\/TEN was 83 and 24 days, respectively.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Overall, in selected cutaneous AEs, each of them showed specific characteristics. It is necessary to realize their differences and take appropriate interventions in patients with different regimens.<\/jats:p>","DOI":"10.3389\/fphar.2023.1076473","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:35:53Z","timestamp":1685698553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Wenchao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyue","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management","volume":"7","author":"Apalla","year":"2021","journal-title":"Int. J. Womens Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ad.2014.02.010","article-title":"Antiangiogenic agents and the skin: Cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab","volume":"105","author":"Ara","year":"2014","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas Engl. Ed."},{"key":"B4","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci. Data"},{"key":"B5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and steven-johnson syndrome: A comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv. Wound Care (New Rochelle)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: A review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: A meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCO.0000000000000466","article-title":"Immunotherapy-based combinations: An update","volume":"30","author":"Fuc\u00e0","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: A systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1159\/000513233","article-title":"Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small-cell lung cancer","volume":"237","author":"Gisondi","year":"2021","journal-title":"Dermatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","article-title":"The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1\/PD-L1 plus anti-CTLA-4): A systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.critrevonc.2013.11.007","article-title":"Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors","volume":"90","author":"Ishak","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune checkpoint inhibitors: An observational, pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J. Invest. Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br. J. Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int. J. Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: Systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front. Oncol."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS)","volume-title":"Data mining applications in engineering and medicine","author":"Poluzzi","year":"2012"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20545","DOI":"10.1097\/MD.0000000000020545","article-title":"Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients","volume":"99","author":"Qiu","year":"2020","journal-title":"Med. Baltim."},{"key":"B25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J. Am. Acad. Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00280-015-2870-0","article-title":"Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1076473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:35:58Z","timestamp":1685698558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1076473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":35,"alternative-id":["10.3389\/fphar.2023.1076473"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1076473","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1076473"}}